Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)

Launched by UNIVERSITY HOSPITAL, GHENT · May 17, 2024

Keywords

ClinConnect Summary

The Pediatric Antibiotic Dosing in Extracorporeal Membrane Oxygenation (PADECMO) trial is studying how different antibiotics behave in the bodies of critically ill children and infants who are on a special life-support machine called extracorporeal membrane oxygenation (ECMO). This research aims to find the best ways to dose these antibiotics, ensuring that patients receive the right amount for their treatment while they are in the pediatric or cardiac intensive care unit.

To participate in this study, children aged between 1.8 kg and 15 years old who are being treated with specific antibiotics like piperacillin-tazobactam, meropenem, or vancomycin may be eligible. They must have a special access line for drawing blood and be on ECMO. If a child joins the study, they will help researchers understand how these medications work in their bodies, which could lead to better treatment options in the future. It's important for families to know that the study requires consent from parents or guardians, and those with certain allergies to the antibiotics being studied cannot participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients admitted to the pediatric intensive care unit or cardiac intensive care unit
• • patient age : 1,8 kg-15 years
• • patient receiving antibiotic treatment (piperacillin-tazobactam, meropenem, amoxicillin-clavulanate, cephazolin, vancomycin, teicoplanin, ciprofloxacin, amikacin)
• • intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)
• • extracorporeal membrane oxygenation circuit
• Exclusion Criteria:
• • no catheter in place for blood sampling
• • absence of parental/patient consent
• • known hypersensitivity to beta-lactam antibiotics and ciprofloxacin

Trial Officials